Search
Related topics are listed below.
Q92-93: Disease Status at Last Evaluation Prior to the Start of the Preparative Regimen
Comprehensive Disease-Specific Manuals » 2015/2115: Juvenile Myelomonocytic Leukemia (JMML) » 2015: JMML Pre-HCT » Q92-93: Disease Status at Last Evaluation Prior to the Start of the Preparative Regimen
Question 92: What was the disease status? Indicate the disease status of JMML at the last evaluation prior to the start of the preparative regimen. If the patient’s disease transformed to AML, do not complete questions 92-93 and continue with the signature…
2015: JMML Pre-HCT
Comprehensive Disease-Specific Manuals » 2015/2115: Juvenile Myelomonocytic Leukemia (JMML) » 2015: JMML Pre-HCT
The Juvenile Myelomonocytic Leukemia Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures JMML-specific pre-HCT data such as: the recipient’s hematologic and cytogenetic findings at the time of diagnosis and prior to the start of the…
Q86-103: Additional Drugs Given in the Peri-Transplant Period
Comprehensive Baseline & Follow-up Manuals » 2000: Recipient Baseline » Q86-103: Additional Drugs Given in the Peri-Transplant Period
Drugs may be given during the peri-transplant (before and after infusion) period to prevent transplant-related complications or facilitate engraftment. Question 86: ALG, ALS, ATG, ATS Anti-Lymphocyte Globulin (ALT), Anti-Lymphocyte Serum (ALS), Anti-Thymocyte…
Q78-95: Laboratory Findings Prior to the Start of the Preparative Regimen / Infusion
Comprehensive Disease-Specific Manuals » 2028/2128: Aplastic Anemia » 2028: Aplastic Anemia Pre-Infusion » Q78-95: Laboratory Findings Prior to the Start of the Preparative Regimen / Infusion
*Laboratory Findings Prior to the Start of the Preparative Regimen / Infusion: For questions 80 – 97, report all findings within two months prior to the start of the preparative regimen. If the assessment was performed multiple times, report the most recent results…
Q86-92: Disease Modifying Therapies
Comprehensive Disease-Specific Manuals » 2030/2130: Sickle Cell Disease (SCD) » 2030: SCD Pre-Infusion » Q86-92: Disease Modifying Therapies
Question 86: Were disease modifying therapies given? (excludes blood transfusions) Indicate if the recipient received disease modifying therapies (see question 87 for a list of common disease modifying therapies) at any time between diagnosis and the start of the…
Q52-104: Disease Assessment between Diagnosis and the Start of the Preparative Regimen
Comprehensive Disease-Specific Manuals » 2034/2134: X-Linked Lymphoproliferative Sydrome (XLP) » 2034: XLP Pre-HCT » Q52-104: Disease Assessment between Diagnosis and the Start of the Preparative Regimen
Question 52: Was HLH present? HLH is an abnormal proliferation of macrophages and histiocytes that leads to the phagocytosis of healthy circulating blood cells. Indicate if the patient developed HLH at any time after diagnosis but prior to the start of the preparative…
Q87-104: Post-HCT / Post-Infusion Therapy
Comprehensive Disease-Specific Manuals » 2057/2157 Myeloproliferative Neoplasms (MPN) » 2157: Myeloproliferative Neoplasm (MPN) Post-Infusion » Q87-104: Post-HCT / Post-Infusion Therapy
Question 87: Was therapy given since the date of last report for reasons other than relapsed, persistent, or progressive disease including detection of minimal residual disease or decreased / loss of donor chimerism? (include any maintenance therapy) Indicate if the…
Q75-107: Pre-HCT Therapy
Comprehensive Disease-Specific Manuals » 2039/2139: Hemophagocytic Lymphohistiocytosis (HLH) » 2039: HLH Pre-HCT » Q75-107: Pre-HCT Therapy
Copy questions 76-107 to report more than one line of therapy. !Lines of Therapy and Subsequent Infusions If this is a subsequent infusion and a 2039 was completed for the previous infusion, lines of therapy do not need to be reported in duplication on the subsequent…
Q1 – 141: Disease Assessment at Diagnosis
Comprehensive Disease-Specific Manuals » 2029/2129: Fanconi Anemia / Constitutional Anemia » 2029: Fanconi Anemia / Constitutional Anemia Pre-HCT » Q1 – 141: Disease Assessment at Diagnosis
Question 1: What was the date of diagnosis of Fanconi Anemia? Report the date of first pathological evaluation (e.g., bone marrow biopsy) or blood/serum assessment (e.g., CBC, peripheral blood smear) that determined the diagnosis of Fanconi anemia. Enter the date the…
Q61-124: Amyloidosis Organ Involvement at Diagnosis
Comprehensive Disease-Specific Manuals » 2016/2116: Plasma Cell Disorders (PCD) » 2016: PCD Pre-Infusion » Q61-124: Amyloidosis Organ Involvement at Diagnosis
!Complete questions 61-124 for patients with amyloidosis. If amyloidosis was not reported as the primary disease for transplant (question 1) or as a preceding / concurrent disorder (question 2), skip to question 125. Questions 61 – 62: Site(s) of tissue with…
Q84 – 94: Specify Existing Organ Impairments
Comprehensive Disease-Specific Manuals » 2058/2158: Thalassemia » 2058: Thalassemia Pre-Infusion » Q84 – 94: Specify Existing Organ Impairments
Reporting Multiple Organ Impairments FormsNet3SM application: Complete questions 84 – 94 for each co-exiting disease or organ impairment by adding an additional instance in the FormsNet3SM application. Paper form submission: Complete questions 84 – 94 for each…
Q92-141: Product Infusion
Comprehensive Baseline & Follow-up Manuals » 2006: Hematopoietic Stem Cell Transplant (HCT) Infusion » Q92-141: Product Infusion
Question 92: Date of this product infusion: Report the date this product was infused. If the product was infused over multiple days, report the first date of infusion. Question 93: Was the entire volume of received product infused? Indicate Yes if the entire volume…
Q75-100: Apheresis Collection
Infection & Miscellaneous Manuals » 2565: Sanofi Mozobil Supplemental Data » Q75-100: Apheresis Collection
Question 75-76: Did the recipient receive blood transfusions (RBCs) during this apheresis collection? Report “Yes” if the recipient received blood transfusions during this apheresis collection. Also, indicate the number of units of RBCs transfused during the…
Q93-119: Other Laboratory Studies
Comprehensive Disease-Specific Manuals » 2030/2130: Sickle Cell Disease (SCD) » 2030: SCD Pre-Infusion » Q93-119: Other Laboratory Studies
Questions 93 – 94: Was hemoglobin electrophoresis performed? Indicate if hemoglobin electrophoresis studies were performed prior to the start of the preparative regimen / infusion. If hemoglobin electrophoresis studies were performed, report Yes and provide the date…
Q51-105: Clinical Status of Recipient Post-HCT
Comprehensive Disease-Specific Manuals » 2033/2133: Wiskott-Aldrich Syndome (WAS) » 2133: WAS Post-HCT » Q51-105: Clinical Status of Recipient Post-HCT
Question 51: Did the recipient experience any types of bleeding (since the date of last report)? Due to WAS-associated thrombocytopenia, bleeding episodes are frequently observed. Indicate whether the recipient experienced any types of bleeding since the date of last…
Q91 – 102: Specify Existing Organ Impairments
Comprehensive Disease-Specific Manuals » 2058/2158: Thalassemia » 2158: Thalassemia Post-Infusion » Q91 – 102: Specify Existing Organ Impairments
*Reporting Multiple Organ Impairments FormsNet3SM application: Complete questions 91 – 102 for each co-exiting disease or organ impairment by adding an additional instance in the FormsNet3SM application. Paper form submission: Complete questions 91 – 102 for each…
Q44-94: Clinical Features Assessed Post-HCT
Comprehensive Disease-Specific Manuals » 2031/2131: Immune Deficiencies (ID) » 2131: ID Post-HCT » Q44-94: Clinical Features Assessed Post-HCT
Infections Identified Post-HCT Specify the presence of all clinically significant infections identified since the date of the last report. Only report an organism once, even if it was identified at the same site in subsequent infections. Question 44:…
Q42-130:Clinical Features Assessed between Diagnosis and the Start of the Preparative Regimen
Comprehensive Disease-Specific Manuals » 2033/2133: Wiskott-Aldrich Syndome (WAS) » 2033: WAS Pre-HCT » Q42-130:Clinical Features Assessed between Diagnosis and the Start of the Preparative Regimen
Infections identified between Diagnosis and the Start of the Preparative Regimen Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. For the purposes of this form, clinically significant…
2016 Manual Updates
Getting Started » Historical Manual Updates » 2016 Manual Updates
December 2016 August 2016 July 2016 June 2016 April 2016 March 2016 February 2016 January 2016 !Hyperlinks Please note, hyperlinks on this page will not work for any manual sections which have been retired and / or replaced by new versions. December 2016 Date…
Q51-103: Disease Detection Since Date of Last Report
Comprehensive Disease-Specific Manuals » 2010/2110: Acute Myelogenous Leukemia (AML) » 2110: AML Post-Infusion » Q51-103: Disease Detection Since Date of Last Report
!Questions 51-103 This section is intended to capture information only on recipients who relapse, have persistent or minimal residual disease in this reporting period. For questions 51, 63, 70, 80, and 87, report “No” or “Unknown” (see instructions…
Q82-156: Pre-HCT / Pre-Infusion Therapy
Comprehensive Disease-Specific Manuals » 2014/2114: Myelodysplastic Syndrome (MDS) » 2014: Myelodysplastic Syndrome (MDS) Pre-Infusion » Q82-156: Pre-HCT / Pre-Infusion Therapy
The FormsNet3SM application allows questions 83-157 to be reported multiple times. Complete these questions for each line of therapy administered on or after the date of diagnosis of MDS and prior to the start of the preparative regimen (or prior to infusion if no…
Q88-171: Most Recent Laboratory Studies
Comprehensive Disease-Specific Manuals » 2014/2114: Myelodysplastic Syndrome (MDS) » 2114: Myelodysplastic Syndrome (MDS) Post-Infusion » Q88-171: Most Recent Laboratory Studies
!Questions 88-99 refer to overlap syndromes including CMMoL; JMML; aCML; MDS/MPN-RS-T; MDS/MPN, unclassifiable; if the diagnosis was other than an overlap syndrome, continue with Were molecular tests for molecular markers performed (e.g., PCR, NGS)?. Questions 88-89:…
Q84-185: Pre-HCT or Pre-Infusion Therapy
Comprehensive Disease-Specific Manuals » 2012/2112: Chronic Myeloid Leukemia (CML) » 2012: CML Pre-Infusion Data » Q84-185: Pre-HCT or Pre-Infusion Therapy
The FormsNet3SM application allows questions 85-185 to be reported multiple times. Complete these questions for each line of therapy administered prior to the start of the preparative regimen (or prior to infusion if no preparative regimen was given). When submitting…
Q51-115: Clinical Features Assessed Between Diagnosis and the Start of the Preparative Regimen
Comprehensive Disease-Specific Manuals » 2031/2131: Immune Deficiencies (ID) » 2031: ID Pre-HCT » Q51-115: Clinical Features Assessed Between Diagnosis and the Start of the Preparative Regimen
Infection Identified between Diagnosis and the Start of the Preparative Regimen Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified…
Q54-109: Organ Parameters of Amyloidosis at the Time of Best Response
Comprehensive Disease-Specific Manuals » 2016/2116: Plasma Cell Disorders (PCD) » 2116: PCD Post-Infusion » Q54-109: Organ Parameters of Amyloidosis at the Time of Best Response
!Complete questions 54-109 for amyloid patients only. If diagnosis was other than amyloidosis or there is no history of it, continue with question 110. The response time for amyloidosis tends to occur well after transplant, so the “best response” to transplant may…
Q75 – 97: Disease Assessment at the Time of Best Response to Infusion
Transplant Essential Data (TED) Manuals » 2450: Post-TED » Q75 – 97: Disease Assessment at the Time of Best Response to Infusion
!Malignant Diseases Only Only complete Disease Assessment at the Time of Best Response to Infusion questions if the HCT being reported was given to treat a malignant disease. If the HCT being reported was given to treat a non-malignant disease, leave these questions…
Q48-94: Disease Detection Since Date of Last Report
Comprehensive Disease-Specific Manuals » 2011/2111: Acute Lymphoblastic Leukemia (ALL) » 2111: ALL Post-Infusion » Q48-94: Disease Detection Since Date of Last Report
!Questions 48-94 This section is intended to capture information only on recipients who relapse, have persistent or minimal residual disease in this reporting period. For questions 48, 54, 61, 71, and 78, report “No” or “Unknown” (see instructions…
Q87 – 119: Comorbid Conditions
Transplant Essential Data (TED) Manuals » 2400: Pre-TED » Q87 – 119: Comorbid Conditions
*Diagnosis of COVID-19 after the start of the preparative regimen: The COVID-19 diagnosis, hospitalization for COVID-19, and mechanical ventilation for COVID-19 questions are intended to capture COVID-19 (SARS-CoV-2) infections diagnosed prior to the start of the…
Q3 – 103: Acute Myelogenous Leukemia
Transplant Essential Data (TED) Manuals » 2402: Disease Classification » Q3 – 103: Acute Myelogenous Leukemia
Acute Myelogenous Leukemia (AML) is a cancer of the white blood cells. It is characterized by the rapid proliferation of abnormal, immature myelocytes, known as myeloblasts, in the bone marrow. This accumulation of blasts in the marrow prevents the formation of healthy…
2400: Pre-TED
Transplant Essential Data (TED) Manuals » 2400: Pre-TED
*The Pre-TED Form is now required for all transplants, including subsequent transplants on the comprehensive report form track. All transplant centers participating in the CIBMTR must submit a Pre-TED (2400) Form for each allogeneic (related or unrelated)…
Q81-91: Comorbid Conditions
Cellular Therapy Manuals » 4000: Cellular Therapy Essential Data Pre-Infusion » Q81-91: Comorbid Conditions
*Diagnosis of COVD-19 after the start of the lymphodepleting therapy: The COVID-19 diagnosis, hospitalization for COVID-19, and mechanical ventilation for COVID-19 questions are intended to capture COVID-19 (SARS-CoV-2) infections diagnosed prior to the start of the…
2018 Manual Updates
Getting Started » Historical Manual Updates » 2018 Manual Updates
December 2018 November 2018 October 2018 September 2018 August 2018 July 2018 June 2018 May 2018 April 2018 March 2018 February 2018 January 2018 Updates made during the current calendar year are included below. For updates prior to 2018, click on the subtopic…
Q62 – 232: Laboratory Values at Diagnosis of Neuroblastoma
Comprehensive Disease-Specific Manuals » 2026/2126: Neuroblastoma » 2026: Neuroblastoma Pre-Infusion » Q62 – 232: Laboratory Values at Diagnosis of Neuroblastoma
*Laboratory Studies at Diagnosis The intent of questions 62 -232 is to capture the laboratory findings at the time of diagnosis. If multiple studies were performed prior to the institution of therapy, report the values closest to the diagnosis date of neuroblastoma.…
Q86 – 134: Acute Graft vs. Host Disease (GVHD)
Comprehensive Baseline & Follow-up Manuals » 2100: Post-Infusion Follow-Up » Q86 – 134: Acute Graft vs. Host Disease (GVHD)
*Autologous Transplants If this was an autologous infusion, continue with the Infection Prophylaxis section. The graft-versus-host disease sections should only be completed if an allogeneic donor was used. !Acute GVHD Prophylaxis Acute GVHD prophylaxis questions can…
2022 Manual Updates
Getting Started » Historical Manual Updates » 2022 Manual Updates
January 2022 February 2022 March 2022 April 2022 May 2022 August 2022 September 2022 October 2022 November 2022 December 2022 Updates made during the current calendar year are included below. For updates prior to 2022, click on the subtopic corresponding to the year…
2020 Manual Updates
Getting Started » Historical Manual Updates » 2020 Manual Updates
January 2020 February 2020 March 2020 April 2020 May 2020 June 2020 July 2020 August 2020 October 2020 December 2020 Updates made during the current calendar year are included below. For updates prior to 2020, click on the subtopic corresponding to the year of…